Amgen receives approval from the United States Food and Drug Administration (FDA) for AMJEVITA™, a biosimilar for adults with psoriasis and psoriatic arthritis.
This announcement follows the September 2022 approval from the U.S. Food and Drug Administration (FDA) and the Japan’s Ministry of Health, Labour, and Welfare.
European Commission grants conditional marketing authorization based on the EFFISAYIL® 1 trial, which showed over half of the spesolimab-treated patients were free of pustules, one week after receiving a single dose. This decision builds on existing approvals in the United States and Japan.
The International Psoriasis Council (IPC) and Scientific Education Support (SES) are excited to announce a strategic collaboration aimed to improve awareness, knowledge, and understanding of psoriasis, psoriatic arthritis, and other related diseases.
New resource page that includes the latest articles, downloads, and related press releases on GPP to assist with diagnosing and treating this rare disease.
Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide and the first improvement in oral treatment for moderate to severe plaque psoriasis in nearly ten years.
Arcutis Biotherapeutics, Inc announced Arcutis Cares, a patient assistance program (PAP) for financially qualified uninsured and underinsured patients.
Claro, a digital platform built to improve mental health for those with psoriasis who are living in Spain, the United Kingdom, and Italy.
Eli Lilly announced a new formula for Taltz® that contains the same active ingredient as the original formulation, but patients experience significantly less pain at the injection site.
ZORYVE is the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved to treat plaque psoriasis. The product is expected to be available mid-August.
Arcutis Biotherapeutics, Inc. shared their finding from the Skin Insights: Uncovering Psoriasis Survey.
Dermavant announced the FDA approval for VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults. This is the first topical novel chemical entity launched for psoriasis in the U.S. in 25 years.
